Literature DB >> 18618083

Loss of visual function after repeated intravitreal injections of triamcinolone acetonide in refractory uveitic macular oedema.

Claudia Schulze-Döbold1, Michel Weber.   

Abstract

PURPOSE: The effects of intravitreal triamcinolone acetonide on macular oedema have been evaluated in many studies. Good short-time effects are usually reported on visual function and macular oedema. However, adverse events like intraocular hypertension and cataract formation have been described in humans, and retinal toxicity is found in experimental studies. CASE REPORT: We report on a 56-year-old male patient with a bilateral macular oedema in idiopathic intermediate uveitis, treated with two and six intravitreal injections of triamcinolone acetonide, respectively, and followed for 6 years.
RESULTS: The macular oedema disappeared after each intravitreal injection, but each time it recidivated some months later. Visual acuity improved only after the first injections. After six intravitreal injections, visual acuity was limited to counting fingers in the absence of macular oedema. OCT and ERG results show central and peripheral retinal damage that could be a consequence of a retinotoxic property of triamcinolone acetonide.
CONCLUSION: Repeated intravitreal injection of triamcinolone acetonide does not show any long-term efficacy on uveitic macular oedema and can even lead to irreversible global retinal damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618083     DOI: 10.1007/s10792-008-9248-9

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  11 in total

1.  Evaluation of intravitreal kenalog toxicity in humans.

Authors:  Yaron Lang; Rina Leibu; Nir Shoham; Benjamin Miller; Ido Perlman
Journal:  Ophthalmology       Date:  2007-01-16       Impact factor: 12.079

2.  Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells.

Authors:  Raja Narayanan; Jeanie K Mungcal; M Cristina Kenney; Gail M Seigel; Baruch D Kuppermann
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-02       Impact factor: 4.799

3.  Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study.

Authors:  Seung-Young Yu; Francisco Max Damico; Francesco Viola; Donald J D'Amico; Lucy H Young
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

4.  Outcome of intravitreal triamcinolone in uveitis.

Authors:  Howesen Kok; Chun Lau; Nicholas Maycock; Peter McCluskey; Susan Lightman
Journal:  Ophthalmology       Date:  2005-09-19       Impact factor: 12.079

Review 5.  Intravitreal triamcinolone acetonide: a change in a paradigm.

Authors:  Jost B Jonas
Journal:  Ophthalmic Res       Date:  2006-06-06       Impact factor: 2.892

6.  Retinal toxicity of intravitreal kenalog in albino rabbits.

Authors:  Yaron Lang; Esther Zemel; Benjamin Miller; Ido Perlman
Journal:  Retina       Date:  2007 Jul-Aug       Impact factor: 4.256

7.  Cytotoxicity of triamcinolone acetonide on human retinal pigment epithelial cells.

Authors:  Yi-Sheng Chang; Chao-Liang Wu; Sung-Huei Tseng; Pao-Ying Kuo; Shih-Ya Tseng
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

8.  A moephologic study of retinal toxicity induced by triamcinolone acetonide vehicles in rabbit eyes.

Authors:  Qian Li; Jingzhao Wang; Lin Yang; Bin Mo; Huiyang Zeng; Ningli Wang; Wu Liu
Journal:  Retina       Date:  2008-03       Impact factor: 4.256

9.  Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children.

Authors:  Ahmed Sallam; Richard M Comer; John H Chang; John R Grigg; Richard Andrews; Peter J McCluskey; Susan Lightman
Journal:  Arch Ophthalmol       Date:  2008-02

Review 10.  Intravitreal steroids for macular edema in diabetes.

Authors:  D Grover; T J Li; C C W Chong
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  3 in total

Review 1.  Sustained-release steroids for the treatment of diabetic macular edema.

Authors:  Alejandra Daruich; Alexandre Matet; Francine Behar-Cohen
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

2.  Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models.

Authors:  Rajendra S Kadam; Narayan P S Cheruvu; Henry F Edelhauser; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

Review 3.  Optical coherence tomography imaging in uveitis.

Authors:  Sumru Onal; Ilknur Tugal-Tutkun; Piergiorgio Neri; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2013-07-09       Impact factor: 2.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.